Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Conditions
Interventions
Pasritamig
Placebo
+1 more
Locations
163
United States
University of California at San Diego
La Jolla, California, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Colorado Clinical Research
Lakewood, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
Start Date
September 2, 2025
Primary Completion Date
May 30, 2028
Completion Date
May 30, 2028
Last Updated
April 13, 2026
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions